Skip to main content

Site notifications

Fintepla UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia

Product name
Fintepla
Accepted date
Nov-2023
Active ingredients
fenfluramine hydrochloride
Proposed indication
For the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).
Application type
C (new indication)
Publication date
Nov-2023

Help us improve the Therapeutic Goods Administration site